Published in J Biol Chem on January 05, 2012
Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB. Nat Cell Biol (2015) 1.88
Developing irreversible inhibitors of the protein kinase cysteinome. Chem Biol (2013) 1.81
Glucose-TOR signalling reprograms the transcriptome and activates meristems. Nature (2013) 1.76
Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence. Cell Cycle (2012) 1.67
mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Lett (2013) 1.40
Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PLoS One (2013) 1.29
mTOR regulates phagosome and entotic vacuole fission. Mol Biol Cell (2013) 1.22
Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Res (2013) 1.16
Mammalian target of rapamycin (mTOR) signaling network in skeletal myogenesis. J Biol Chem (2012) 1.13
The role of target of rapamycin signaling networks in plant growth and metabolism. Plant Physiol (2014) 1.06
Rapamycin has a biphasic effect on insulin sensitivity in C2C12 myotubes due to sequential disruption of mTORC1 and mTORC2. Front Genet (2012) 1.03
Master Regulators in Plant Glucose Signaling Networks. (2014) 1.00
mTOR: a link from the extracellular milieu to transcriptional regulation of oligodendrocyte development. ASN Neuro (2013) 0.99
IL-33 induces innate lymphoid cell-mediated airway inflammation by activating mammalian target of rapamycin. J Allergy Clin Immunol (2012) 0.98
ATP-competitive mTOR kinase inhibitors delay plant growth by triggering early differentiation of meristematic cells but no developmental patterning change. J Exp Bot (2013) 0.97
A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models. PLoS One (2013) 0.92
Torin1-mediated TOR kinase inhibition reduces Wee1 levels and advances mitotic commitment in fission yeast and HeLa cells. J Cell Sci (2014) 0.89
Novel links in the plant TOR kinase signaling network. Curr Opin Plant Biol (2015) 0.88
Emerging role of mTOR in the response to cancer therapeutics. Trends Cancer (2016) 0.86
Rapamycin-insensitive mTORC1 activity controls eIF4E:4E-BP1 binding. F1000Res (2012) 0.84
Profiling protein kinases and other ATP binding proteins in Arabidopsis using Acyl-ATP probes. Mol Cell Proteomics (2013) 0.83
mTOR kinase: a possible pharmacological target in the management of chronic pain. Biomed Res Int (2015) 0.82
mTOR and differential activation of mitochondria orchestrate neutrophil chemotaxis. J Cell Biol (2015) 0.81
Autophagy knocked down by high-risk HPV infection and uterine cervical carcinogenesis. Int J Clin Exp Med (2015) 0.80
Mirk/dyrk1B kinase is upregulated following inhibition of mTOR. Carcinogenesis (2014) 0.79
Chemoproteomic profiling identifies changes in DNA-PK as markers of early dengue virus infection. ACS Chem Biol (2012) 0.79
Inhibition of the Mechanistic Target of Rapamycin (mTOR)-Rapamycin and Beyond. Cold Spring Harb Perspect Med (2016) 0.78
Differential TOR activation and cell proliferation in Arabidopsis root and shoot apexes. Proc Natl Acad Sci U S A (2017) 0.77
Structural biology: Security measures of a master regulator. Nature (2013) 0.77
Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives. Front Pharmacol (2016) 0.77
Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair. Radiat Res (2016) 0.75
Structural and Biochemical Basis for Intracellular Kinase Inhibition by Src-specific Peptidic Macrocycles. Cell Chem Biol (2016) 0.75
CZ415, a Highly Selective mTOR Inhibitor Showing in Vivo Efficacy in a Collagen Induced Arthritis Model. ACS Med Chem Lett (2016) 0.75
mTORC1 and 2 coordinate transcriptional and translational reprogramming in resistance to DNA damage and replicative stress in breast cancer cells. Mol Cell Biol (2016) 0.75
The small molecule AUTEN-99 (autophagy enhancer-99) prevents the progression of neurodegenerative symptoms. Sci Rep (2017) 0.75
SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res (2003) 25.86
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol (2004) 12.12
Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell (2002) 11.50
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov (2009) 10.59
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol (2009) 9.63
Two adenovirus mRNAs have a common 5' terminal leader sequence encoded at least 10 kb upstream from their main coding regions. Cell (1977) 6.72
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene (2006) 6.54
Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem (1995) 5.57
Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol (2006) 5.03
Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov (2006) 4.56
AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res (2009) 4.50
Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene (1998) 4.31
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J (2009) 4.12
PI 3-kinase related kinases: 'big' players in stress-induced signaling pathways. DNA Repair (Amst) (2004) 3.85
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol (2008) 3.84
Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell (2010) 3.33
A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol (2011) 3.10
Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res (2009) 3.03
Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry (2007) 3.01
Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell (2008) 2.32
Adaptive informatics for multifactorial and high-content biological data. Nat Methods (2011) 2.16
Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res (2010) 1.86
Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood (2000) 1.52
Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther (2011) 1.45
mTOR Mediated Anti-Cancer Drug Discovery. Drug Discov Today Ther Strateg (2009) 1.41
Optimal targeting of the mTORC1 kinase in human cancer. Curr Opin Cell Biol (2009) 1.27
DataPflex: a MATLAB-based tool for the manipulation and visualization of multidimensional datasets. Bioinformatics (2009) 0.92
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol (2006) 32.51
mTOR signaling in growth control and disease. Cell (2012) 29.21
Defining the role of mTOR in cancer. Cancer Cell (2007) 21.63
mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol (2010) 21.16
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 18.84
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell (2002) 18.22
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
CellProfiler: free, versatile software for automated biological image analysis. Biotechniques (2007) 14.71
The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science (2008) 14.08
ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res (2003) 12.81
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73
Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell (2010) 12.24
Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast proteome. J Proteome Res (2003) 11.96
Cancer cell metabolism: Warburg and beyond. Cell (2008) 11.80
Growing roles for the mTOR pathway. Curr Opin Cell Biol (2005) 11.66
Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell (2006) 11.48
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
Genetic screens in human cells using the CRISPR-Cas9 system. Science (2013) 10.75
A proteomics approach to understanding protein ubiquitination. Nat Biotechnol (2003) 10.51
Large-scale sequence analysis of avian influenza isolates. Science (2006) 9.87
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell (2007) 9.68
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29
Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer (2009) 9.26
mTOR signaling at a glance. J Cell Sci (2009) 8.66
Acute lymphoblastic leukaemia. Lancet (2008) 8.54
Cells on chips. Nature (2006) 8.40
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23
Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 8.07
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature (2011) 8.03
Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell (2010) 7.59
mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science (2011) 7.55
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol (2002) 7.44
Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature (2009) 7.24
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature (2009) 7.05
Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 6.80
NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A (2006) 6.80
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science (2011) 6.75
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res (2008) 6.71
Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science (2012) 6.69
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell (2002) 6.64
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
A unifying model for mTORC1-mediated regulation of mRNA translation. Nature (2012) 6.44
DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell (2009) 5.97
Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96
Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell (2012) 5.92
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65
A tissue-scale gradient of hydrogen peroxide mediates rapid wound detection in zebrafish. Nature (2009) 5.55
Timing and checkpoints in the regulation of mitotic progression. Dev Cell (2004) 5.41
The pharmacology of mTOR inhibition. Sci Signal (2009) 5.36
Informatics and quantitative analysis in biological imaging. Science (2003) 5.22
GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell (2003) 5.21
The Open Microscopy Environment (OME) Data Model and XML file: open tools for informatics and quantitative analysis in biological imaging. Genome Biol (2005) 5.16
Scoring diverse cellular morphologies in image-based screens with iterative feedback and machine learning. Proc Natl Acad Sci U S A (2009) 5.15
mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol (2006) 5.06
A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J (2012) 5.03
Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol (2006) 5.03
Towards a rigorous assessment of systems biology models: the DREAM3 challenges. PLoS One (2010) 4.94
Genome sequence of Shigella flexneri 2a: insights into pathogenicity through comparison with genomes of Escherichia coli K12 and O157. Nucleic Acids Res (2002) 4.92
Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med (2005) 4.92
The yeast DASH complex forms closed rings on microtubules. Nat Struct Mol Biol (2005) 4.81
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc Natl Acad Sci U S A (2008) 4.80
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol (2002) 4.77
A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis. Science (2005) 4.75
mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell (2011) 4.70
FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med (2007) 4.59
An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum Mol Genet (2006) 4.56
Physicochemical modelling of cell signalling pathways. Nat Cell Biol (2006) 4.34
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res (2011) 4.22
tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. Proc Natl Acad Sci U S A (2005) 4.15
Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities. Nature (2007) 4.14
Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods (2006) 4.12
TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol (2003) 4.01
A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science (2013) 3.96
Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. Genome Res (2010) 3.94
Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer (2006) 3.89
Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. Mol Cell (2008) 3.88